Out of stock

ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন

0 People recently viewed this

Lorbrexen 100

Name: Lorbrexen 100mg Tablet
Brand: Everest Pharmaceuticals Ltd.
SKU: 39527
Price: 92112 BDT
Availability: InStock
Rating: 4.9 (1 reviews)

Tablet - (100mg)

Everest Pharmaceuticals Ltd.

Generic: Lorlatinib

Medicine Overview of Lorbrexen 100mg Tablet

বাংলা

English

Indication

Non-small Cell Lung Cancer

Adult Dose

Non-small Cell Lung Cancer Indications Indicated for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on the following Crizotinib and at least 1 other ALK inhibitor, OR Alectinib or ceritinib as first ALK inhibitor therapy 100 mg PO qDay with or without food Continue until disease progression or unacceptable toxicity Hepatic impairment Mild (total bilirubin ?ULN with AST >ULN or total bilirubin >1-1.5x ULN with any AST): No dose adjustment necessary Moderate or severe: Recommended dose not established

Renal Dose

Renal impairment Mild or moderate (CrCl 30-89 mL/min): No dosage adjustment necessary Severe (CrCl <30 mL/min): Recommended dose not established

Contraindication

Coadministration with strong CYP3A inducers

Mode of Action

ALK/ROS1 tyrosine kinase inhibitor ALK and ROS1 kinases promote tumor progression in ALK/ROS1 positive lung cancer; lorlatinib binds to and inhibits both kinases, which leads to a disruption of the ALK- and ROS1-mediated signaling; this disruption can subsequently inhibit tumor cell growth in ALK- and ROS1-overexpressing tumor cells

Precaution

Severe hepatotoxicity occurred in healthy subjects receiving lorlatinib with rifampin, a strong CYP3A inducer; consider discontinuing lorlatinib or CYP3A inducer for persistent Grade ≥2 hepatotoxicity (see Contraindications) CNS effects (eg, seizures, hallucinations, changes in cognitive function, mood [including suicidal ideation]) may occur Increased serum cholesterol and triglycerides may occur; initiate or increase dose of lipid-lowering agents in patients with hyperlipidemia; monitor serum cholesterol and triglycerides PR interval prolongation and AV block reported; monitor ECG before initiating treatment and periodically thereafter Severe or life-threatening pulmonary adverse reactions consistent with ILD/pneumonitis can occur

Side Effect

>10% Hypercholesterolemia (96%) Hypertriglyceridemia (90%) Edema (57%) Hyperglycemia (52%) Anemia (52%) Peripheral neuropathy (47%) Increased AST (37%) Hypoalbuminemia (33%) Increased ALT (28%) Cognitive effects (27%) Dyspnea (27%) Fatigue (26%) Weight gain (24%) Increased lipase (24%) Increased alkaline phosphatase (24%) Thrombocytopenia (23%) Arthralgia (23%) Mood effects (23%) Diarrhea (22%) Increased amylase (22%) Lymphopenia (22%) Hyperkalemia (21%) Hypomagnesemia (21%) Headache (18%) Cough (18%) Nausea (18%) Myalgia (17%) Dizziness (16%) Vision disorder (15%) Constipation (15%) Rash (14%) Back pain (13%) Pain in extremity (13%) Vomiting (12%) Speech effects (12%) Pyrexia (12%) Upper respiratory tract infection (12%) Grades 3 or 4 Hypercholesterolemia (18%) Hypertriglyceridemia...

... Show more

Pregnancy Category Note

Pregnancy Based on findings from animal studies and its mechanism of action, embryo-fetal harm may occur when administered to a pregnant woman No available data on use in pregnant women Advise pregnant women of the potential risk to fetus Verify pregnancy status in females of reproductive potential before initiating treatment Animal data Administration of lorlatinib to pregnant rats and rabbits by oral gavage during organogenesis resulted in malformations, increased postimplantation loss, and abortion at maternal exposures that were equal to or less than the human exposure at 100 mg qDay Contraception Female patients of reproductive potential: Use effective nonhormonal contraception...

... Show more

Interaction

CYP3A4 inducers Coadministration with strong CYP3A inducers decrease lorlatinib plasma concentrations Effect of moderate CYP3A inducer on lorlatinib plasma concentrations not studied; if coadministration unavoidable, monitor ALT, AST, and bilirubin CYP3A4 inhibitors Coadministration with strong CYP3A inhibitors increased lorlatinib plasma concentrations CYP3A substrates Coadministration with CYP3A substrates decreases concentration of CYP3A substrates, which may reduce the efficacy of these substrates Avoid use with CYP3A substrates with narrow therapeutic index; if coadministration unavoidable, increase dose of CYP3A substrate in accordance to prescribing information

ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন

0 People recently viewed this

Lorbrexen 100

Tablet - (100mg)

Everest Pharmaceuticals Ltd.

Generic: Lorlatinib

Additional Offers

Cashback

৳50

For purchasing above ৳5000+

Cashback

৳40

For purchasing above ৳4000+

Cashback

৳30

For purchasing above ৳3000+

Cashback

৳20

For purchasing above ৳2000+

Cashback

৳10

For purchasing above ৳1000+

Disclaimer

The information provided herein is accurate, updated and complete as per the best practices of the Company. Please note that this information should not be treated as a replacement for physical medical consultation or advice. We do not guarantee the accuracy and the completeness of the information so provided. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company. We do not take any responsibility for the consequences arising out of the aforementioned information and strongly recommend you for a physical consultation in case of any queries or doubts.